CSE: PHRMOTCQB: PHRRF
Contact us
Menu

503A compounding · First launches Q4 2026

From injection to a printed oral dose.

Printed chewables, dissolvable tablets and multi-layer combinations, prepared by licensed 503A pharmacies for individual patients and offered through telehealth partners.

Q4 2026First launches: Rx wellness and 503A-eligible peptides
Q1 2027Ketamine dissolvable tablet for telehealth
If FDA rulemaking allowsAdditional peptides, such as BPC-157

The line-up

Three product families, one printing platform.

Rx wellness · Q4 2026

NAD+ and glutathione

Printed as chewables and dissolvable tablets, each made at the dose prescribed.

503A-eligible peptides · Q4 2026

Sermorelin and PT-141

Most peptides are injected today. We print them as chewables, dissolvable tablets and multi-layer combinations.

Telehealth · Q1 2027

Ketamine dissolvable tablet

Dosed from 10 mg to 100 mg for precise titration through 503A pharmacies and telehealth partners.

Next, if the FDA allowsPeptides such as BPC-157 may follow only if the FDA completes the required rulemaking.

Why printing

The exact dose, in a form patients prefer.

One validated formulation prints any strength, so each prescription is made at the dose prescribed, with no splitting or crushing, and several actives or release speeds can share one unit.

±1%Dose accuracy
Multi-layerSeveral actives or release speeds in one unit
No heat, no UVGentle on peptides and other heat-sensitive actives
Per patientEach prescription printed at the dose prescribed

Ketamine

The molecule we know.

PharmaTher developed an FDA-approved ketamine ANDA, which it sold in December 2025. Our ketamine dissolvable tablet builds on that experience: one formulation, printed from 10 mg to 100 mg, for precise titration through 503A pharmacies and telehealth partners.

Our ketamine assets →
10 mg25 mg50 mg75 mg100 mgKETAMINE ODTone formulationTELEHEALTH10–100 mg, fine stepsCOUNTERMEASURES25–100 mg bandsPrinted size sets the dose. Illustrative.

White-label for telehealth brands

Pharma, peptide and nutraceutical products under your own brand, fulfilled through our U.S. Center of Excellence.

Talk to us about white-label supply

Investors

The corporate presentation covers every product and launch milestone.

Download the deck (PDF)

Compounded drugs are not approved by the FDA. 503A products are patient-specific prescriptions prepared by licensed pharmacies, and 503A eligibility is confirmed for each product before launch. Certain peptides, including BPC-157, may not be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act unless and until the FDA completes the applicable rulemaking. Ketamine is a controlled substance, and its compounding, manufacture and distribution require registrations with the DEA. PharmaTher does not sell directly to patients. Timelines are internal estimates and forward-looking.